Hambrecht & Quist Capital Management
VC Fund
Boston, United States
Hambrecht & Quist Capital Management is a VC fund in Boston focused on Biotechnology and Health Care. Now known as Tekla Capital Management LLC. Hambrecht & Quist Capital Management, LLC ("HQCM"), a registered investment adviser based in Boston, Massachusetts, is currently the investment adviser for two closed-end equity funds, H&Q Healthcare Investors and H&Q Life Sciences Investors. The Funds invest in growth equities, bothpublic and private, in the healthcare and life sciences industries.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Hambrecht & Quist Capital Management invests in
BiotechnologyHealth CarePharmaceuticalMedicalInternet
Stages Hambrecht & Quist Capital Management invests in
Series CFunding RoundSeries BSeries DSeries A
Countries Hambrecht & Quist Capital Management invests in
United StatesCanada
Round sizes
Series B $9.7M–$38MSeries C $18M–$65M
Round size
- Series B
- $9.7M–$38M
- Series C
- $18M–$65M
Investment Focus
Industry
- Biotechnology 11 (42%)
- Health Care 7 (27%)
- Pharmaceutical 6 (23%)
- Medical 3 (12%)
- Internet 3 (12%)
Stage
- Series C 7 (27%)
- Funding Round 5 (19%)
- Series B 4 (15%)
- Series D 4 (15%)
- Series A 1 (4%)
Country
- United States 19 (73%)
- Canada 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Veniti
|
VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum.Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous diseasecycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux.The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease. | $9.7M / Series B / Jun 04, 2013 | |
|
Veniti
|
VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum.Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous diseasecycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux.The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease. | $13.5M / Series A / Mar 07, 2011 | |
Eleme Medical
|
Elemé Medical, Inc. is a venture backed aesthetics company dedicated to providing market-leading technology in all areas of body shaping. The newly launched SmoothShapes® XV will revolutionize how cellulite is treated and introduce exciting new protocols for pre and post liposuction care. With 50% more laser power, SmoothSpeed™ audible &visual treatment guidance and a portable, sleek console design, SmoothShapes XV is an ideal way to add non-invasive body shaping to a practice. SmoothShapes XV is the newest product launched by the Company and joins the original SmoothShapes launched in 2008, both products are a CE Marked, FDA-cleared medical devices for the temporary reduction in the appearance of cellulite.Both SmoothShapes systems are based on the company's proprietary Photomology® platform – a process that treats cellulite and subcutaneous fat by combining dynamic light and laser energy along with mechanical manipulation (vacuum and massage). The system addresses the physical manifestations of cellulite and its underlying causes providing long lasting results that patients can see and feel.Targets include plastic surgeons, aesthetic dermatologists, medical spas and other aesthetic physicians. According to Global Body Shaping Market Analysis, body shaping is one of the top growth areas in the Aesthetics market with 19% growth through the year 2012. The global aesthetics market is projected to grow from $5.0 billion in 2008 to $8.1 billion by 2011. | $18M / Series C / Jul 16, 2008 | |
FlowCardia
|
FlowCardia, Inc. is a medical device company founded in 2002 to design and develop a portfolio of innovative, catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. Chronic Total Occlusions (CTOs) are considered one of the last major clinical challenges in interventional therapy. Thehistoric absence of safe and effective CTO recanalization devices is a major reason a large number of patients are still referred to coronary and peripheral bypass surgery and lower limb amputation. | $30M / Series C / Aug 30, 2007 | |
TargeGen
|
TargeGen, Inc., a vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. The company offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascularleakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions. It serves macular degeneration, diabetic macular edema, and diabetic retinopathy markets. The company was founded in 2002 and is based in San Diego, California. It was acquired by | $40M / Series D / Jul 12, 2007 | |
Athersys
|
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and improve the quality of human life. The product development portfolio of the Company includes MultiStem, a stem cell product, which is being developed as a treatment for multiple disease indications, and is beingevaluated in two ongoing clinical trials, and has been authorized for use in a third clinical trial. In addition, the Company is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, and narcolepsy or other forms of excessive daytime sleepiness. | $65M / Jun 12, 2007 | |
Xoft
|
Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breastirradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California. | $33.2M / Series D / Apr 05, 2007 | |
Xanthus Pharmaceuticals
|
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders. | $25M / Series B / Dec 01, 2006 | |
Raven Biotechnologies
|
Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 andis based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc. | $48.3M / Series D / Oct 24, 2005 | |
Idun Pharmaceuticals
|
IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected withHepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc. | $27M / Series B / Jun 15, 2004 | |
| See all 26 investments → | |||
Co-Investors
MPM Capital
4 deals together
OrbiMed
4 deals together
CDP Capital Technology Ventures
3 deals together
GeneChem
3 deals together
Baird Capital
2 deals together
Bear Stearns Health Innoventures L.P
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
99,274 investors
Enterprise Investors
77,348 investors
Health Care Investors
43,014 investors
Internet Investors
23,697 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
SaaS VC Funds
61,208 investors
Enterprise VC Funds
49,693 investors
FAQ
What does Hambrecht & Quist Capital Management invest in?
Hambrecht & Quist Capital Management invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series C and Funding Round stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Hambrecht & Quist Capital Management's check size?
Hambrecht & Quist Capital Management typically joins rounds of $9.7M–$38M at Series B and $18M–$65M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Hambrecht & Quist Capital Management participates in.
When did Hambrecht & Quist Capital Management last invest?
The most recent investment recorded for Hambrecht & Quist Capital Management closed in Jun 2013. Shizune tracks 26 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
